Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in SeptemberGlobeNewsWire • 09/02/25
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo NordiskInvestors Business Daily • 08/28/25
Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive QuartersThe Motley Fool • 08/20/25
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The UpsideSeeking Alpha • 07/31/25
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call TranscriptSeeking Alpha • 07/30/25
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/30/25
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 EarningsInvestors Business Daily • 07/30/25
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 07/29/25
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive QuartersThe Motley Fool • 07/18/25
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?Zacks Investment Research • 07/11/25
Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead24/7 Wall Street • 07/01/25
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025GlobeNewsWire • 06/25/25
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?The Motley Fool • 06/25/25
Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic MigraineGlobeNewsWire • 06/23/25
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer TherapyZacks Investment Research • 06/17/25
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-OncologyPRNewsWire • 06/16/25
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight QuartersThe Motley Fool • 06/16/25